Complement dysregulation in glomerulonephritis.
Animals
Bacterial Infections
/ complications
Biomarkers
Complement Activation
/ genetics
Complement System Proteins
/ immunology
Disease Susceptibility
/ immunology
Glomerulonephritis
/ diagnosis
Glomerulonephritis, IGA
/ etiology
Glomerulonephritis, Membranoproliferative
/ etiology
Hemolytic-Uremic Syndrome
/ etiology
Humans
C3 glomerulonephritis
C3 glomerulopathy
C3 nephritic factor
C3GN
C3bBb
Complement
Dense deposit disease
Eculizumab
FHR
Factor H
Factor H-related protein
Hemolytic uremic syndrome
IgA glomerulonephritis
IgA nephropathy
Membranoproliferative glomerulonephritis
Plasmapheresis
Proteinuria
Sialic acid
Streptococcus
aHUS
Journal
Seminars in immunology
ISSN: 1096-3618
Titre abrégé: Semin Immunol
Pays: England
ID NLM: 9009458
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
13
11
2019
medline:
5
6
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
Glomerulonephritis (GN) refers to a group of renal diseases affecting the glomeruli due to the damage mediated by immunological mechanisms. A large proportion of the disease manifestations are caused by disturbances in the complement system. They can be due to genetic errors, autoimmunity, microbes or abnormal immunoglobulins, like modified IgA or paraproteins. The common denominator in most of the problems is an overactive or misdirected alternative pathway complement activation. An assessment of kidney function, amount of proteinuria and hematuria are crucial elements to evaluate, when glomerulonephritis is suspected. However, the cornerstones of the diagnoses are renal biopsy and careful examination of the complement abnormality. Differential diagnostics between the various forms of GN is not possible based on clinical features, as they may vary greatly. This review describes the known mechanisms of complement dysfunction leading to different forms of primary GN (like IgA glomerulonephritis, dense deposit disease, C3 glomerulonephritis, post-infectious GN, membranous GN) and differences to atypical hemolytic uremic syndrome. It also covers the basic elements of etiology-directed therapy and prognosis of the most common forms of GN. Common principles in the management of GN include treatment of hypertension and reduction of proteinuria, some require immunomodulating treatment. Complement inhibition is an emerging treatment option. A thorough understanding of the basic disease mechanism and a careful follow-up are needed for optimal therapy.
Identifiants
pubmed: 31711769
pii: S1044-5323(19)30084-3
doi: 10.1016/j.smim.2019.101331
pii:
doi:
Substances chimiques
Biomarkers
0
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101331Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.